For many people, the flu is an unpleasant but temporary illness. A few days of fever, cough, sore throat, body aches, and fatigue are followed by recovery and a return to normal life.
However, for older adults, influenza can be much more dangerous. What starts as a simple infection can quickly develop into serious complications that require hospital treatment.
Health experts have long recognized that adults over 65 face a higher risk of severe illness from influenza. As the body ages, the immune system becomes less efficient at recognizing and fighting viruses. This makes it harder for older people to defend themselves against infections and can reduce the effectiveness of standard vaccines.
To address this problem, vaccine developers created a high-dose influenza vaccine specifically designed for older adults. The vaccine contains four times more antigen than a regular flu shot.
Antigens are the components that teach the immune system how to recognize and respond to the influenza virus. By increasing the amount of antigen, scientists hoped to generate a stronger protective response.
A new study published in JAMA Network Open has now provided some of the strongest evidence yet that this approach works. Researchers combined data from eight large clinical trials involving more than 605,000 participants.
Their goal was to determine whether the high-dose vaccine provided better protection than the standard flu vaccine in adults aged 65 and older.
The findings showed that the stronger vaccine delivered important benefits. People who received the high-dose flu shot were much less likely to be hospitalized because of influenza. The risk of flu-related hospitalization was reduced by 38.5 percent. Hospitalization for laboratory-confirmed influenza was reduced by 31.2 percent.
The benefits extended beyond flu infections alone. Researchers also found reductions in hospital admissions for pneumonia and influenza combined, as well as fewer hospitalizations related to heart and lung conditions. Overall hospital admissions were also slightly lower among people who received the high-dose vaccine.
These results are significant because influenza often affects much more than the lungs. In vulnerable individuals, the virus can trigger widespread inflammation throughout the body.
This can worsen existing health conditions and lead to serious complications. Pneumonia is one of the most common and dangerous consequences, but influenza can also contribute to heart attacks, worsening heart failure, respiratory failure, and kidney problems.
Many people underestimate how serious influenza can be. Each year, seasonal flu causes hundreds of thousands of hospitalizations worldwide.
Older adults account for a large proportion of these cases because they are more likely to develop complications. Preventing even a fraction of these hospital admissions can have major benefits for patients, families, and healthcare systems.
The researchers included participants from North America and Western Europe. The study population represented a broad range of older adults, including those living independently, those residing in nursing homes, and those with pre-existing heart disease.
Importantly, the advantages of the high-dose vaccine remained consistent across different age groups, including individuals aged 80 and older.
One finding surprised some observers. Although the high-dose vaccine reduced hospitalizations, it did not significantly lower the risk of death compared with the standard vaccine. This suggests that while the stronger vaccine can help prevent severe illness that requires hospitalization, its impact on overall mortality may be more limited or may require even larger studies to detect.
The study also builds on earlier research. Previous investigations had shown that high-dose vaccines were better at preventing laboratory-confirmed influenza infections. The new analysis goes a step further by demonstrating that the benefits extend to clinically important outcomes such as hospitalization.
Public health experts are increasingly interested in these outcomes because they have direct consequences for healthcare systems.
During severe flu seasons, hospitals can become overcrowded with patients suffering from influenza and its complications. Vaccines that reduce hospitalization rates can help ease this burden while improving patient outcomes.
The study has several strengths. It combined evidence from multiple randomized clinical trials and included a very large number of participants. This increases confidence in the findings and helps reduce the influence of chance results.
However, some limitations remain. Influenza viruses change from year to year, and vaccine performance can vary depending on how well the vaccine matches circulating strains. In addition, the study focused specifically on older adults, so the findings cannot automatically be applied to younger populations.
Overall, the evidence suggests that the high-dose influenza vaccine offers meaningful extra protection for adults aged 65 and older. By reducing the risk of hospitalization and serious flu-related complications, the vaccine may help older adults remain healthier during flu season.
The findings also carry an important public health message. For seniors, the choice of flu vaccine may matter more than many people realize. While both standard and high-dose vaccines provide protection, the stronger version appears to offer an additional layer of defense against one of the most common and potentially dangerous infections of later life.
If you care about heart disease, please read studies that herbal supplements could harm your heart rhythm, and how eating eggs can help reduce heart disease risk.
For more health information, please see recent studies that apple juice could benefit your heart health, and results showing yogurt may help lower the death risks in heart disease.
Source: JAMA Network Open.
